First Trust Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.52M | Buy |
727,470
+241,988
| +50% | +$2.17M | 0.01% | 1237 |
|
|
2025
Q1 | $3.64M | Sell |
485,482
-79,733
| -14% | -$598K | ﹤0.01% | 1487 |
|
|
2024
Q4 | $4.25M | Sell |
565,215
-28,251
| -5% | -$212K | ﹤0.01% | 1454 |
|
|
2024
Q3 | $4.51M | Buy |
+593,466
| New | +$4.51M | ﹤0.01% | 1382 |
|
|
2024
Q2 | – | Sell |
-141,387
| Closed | -$718K | – | 2321 |
|
|
2024
Q1 | $718K | Sell |
141,387
-19,337
| -12% | -$98.2K | ﹤0.01% | 2064 |
|
|
2023
Q4 | $963K | Buy |
+160,724
| New | +$963K | ﹤0.01% | 1977 |
|
|
2023
Q3 | – | Sell |
-176,763
| Closed | -$1.24M | – | 2359 |
|
|
2023
Q2 | $1.24M | Buy |
176,763
+13,600
| +8% | +$95.7K | ﹤0.01% | 1916 |
|
|
2023
Q1 | $1.36M | Sell |
163,163
-40,471
| -20% | -$338K | ﹤0.01% | 1858 |
|
|
2022
Q4 | $2.34M | Buy |
203,634
+78,566
| +63% | +$902K | ﹤0.01% | 1628 |
|
|
2022
Q3 | $1.58M | Sell |
125,068
-159,783
| -56% | -$2.01M | ﹤0.01% | 1805 |
|
|
2022
Q2 | $3.01M | Buy |
284,851
+109,834
| +63% | +$1.16M | ﹤0.01% | 1544 |
|
|
2022
Q1 | $2.85M | Sell |
175,017
-130,734
| -43% | -$2.13M | ﹤0.01% | 1631 |
|
|
2021
Q4 | $4.24M | Buy |
305,751
+59,305
| +24% | +$821K | ﹤0.01% | 1444 |
|
|
2021
Q3 | $3.54M | Sell |
246,446
-100,387
| -29% | -$1.44M | ﹤0.01% | 1520 |
|
|
2021
Q2 | $5.48M | Buy |
+346,833
| New | +$5.48M | 0.01% | 1294 |
|
|
2019
Q3 | – | Sell |
-49,667
| Closed | -$188K | – | 2397 |
|
|
2019
Q2 | $188K | Buy |
+49,667
| New | +$188K | ﹤0.01% | 2363 |
|